mProX™ Human EPCAM Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human EPCAM Stable Cell Line (S01YF-1023-PY191). Click the button above to contact us or submit your feedback about this product.
Casey Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Taylor Brown (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The growth of MCF-7 and MDA-MB-231 cells is promoted by EpCAM.
EpCAM expression plasmid (0.4ng, 1.0ng, 1.6ng, respectively) was transfected into cells. Confirmation of EpCAM expression was achieved through Western blot analysis. Controls were established using cells transfected with an empty vector. A significant difference (P < 0.01) was observed. Inhibition of foci formation in monolayer culture by EpCAM was demonstrated, and quantitative analyses of foci numbers were conducted. The mean of at least three independent experiments was calculated for columns, with standard deviation represented by bars. A highly significant difference (P < 0.001) was observed.
Ref: Gao, Jiujiao, et al. "By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis." Oncotarget 6.29 (2015): 27187.
Pubmed: 26356670
DOI: 10.18632/oncotarget.4551
Research Highlights
L Eikenboom, Ellis. et al. "Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study." The lancet. Gastroenterology & hepatology, 2023.
The study evaluated the risk of metachronous colorectal cancer in individuals with Lynch syndrome who underwent either partial or extensive colectomy. This procedure is commonly recommended for patients with colorectal cancer and Lynch syndrome, but the risk of metachronous cancer may vary depending on the specific variant of Lynch syndrome. The findings suggest that partial colectomy may be sufficient for those with low-risk variants, providing better functional outcomes compared to extensive colectomy.
L Eikenboom, Ellis. et al. "Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study." The lancet. Gastroenterology & hepatology, 2023.
Pubmed:
37865103
DOI:
10.1016/S2468-1253(23)00228-5
Akagi, Jun-Ichi. et al. "EpCAM and APN expression in combination with γ-H2AX as biomarkers for detecting hepatocarcinogens in rats."" Cancer science, 2023.
Histone H2AX, in its phosphorylated form known as γ-H2AX, has been widely used as a biomarker to assess DNA damage. Drawing from prior research showing γ-H2AX foci as a reliable indicator for identifying bladder carcinogens in a 28-day rat study, it was hypothesized that γ-H2AX could also serve as a marker for detecting hepatocarcinogens. However, this hypothesis was not supported, as hepatocarcinogens lacking hepatocyte proliferation stimulation failed to induce γ-H2AX foci formation. Consequently, alternative biomarkers were explored, revealing increased expression of epithelial cell adhesion molecule (EpCAM/CD326) and aminopeptidase N (APN/CD13) in hepatocytes exposed to various hepatocarcinogens. These findings suggest the potential utility of EpCAM and APN, in conjunction with γ-H2AX, for detecting chemical hepatocarcinogenicity.
Akagi, Jun-Ichi. et al. "EpCAM and APN expression in combination with γ-H2AX as biomarkers for detecting hepatocarcinogens in rats."" Cancer science, 2023.
Pubmed:
37858605
DOI:
10.1111/cas.15990
